RingelMD, SosaJA, BalochZ, et al.2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid2025;35(8):841-985; doi: 10.1177/10507256251363120.
2.
PaciniF, FuhrerD, EliseiR, et al.2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J2022;11(1):e210046; doi: 10.1530/ETJ-21-0046.
3.
WeisH, WeindlerJ, SchmidtK, et al.Impact of radioactive iodine treatment on long-term relative survival in patients with papillary and follicular thyroid cancer: a SEER-based study covering histologic subtypes and recurrence risk categories. J Nucl Med2025;66:525-530; doi: 10.2967/jnumed.124.269091.
4.
SchmidtM, BartensteinP, BuceriusJ, et al.Individualized treatment of differentiated thyroid cancer: the value of surgery in combination with radioiodine imaging and therapy—a German position paper from Surgery and Nuclear Medicine. Nuklearmedizin2022;61:87-96; doi: 10.1055/a-1783-8154.
5.
MakkarN, OstromQT, KruchkoC, Barnholtz-SloanJS. A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations. Cancer Med2018;7(9):4773-4780; doi: 10.1002/cam4.1706.
6.
LeboulleuxS, BournaudC, ChougnetCN, et al.Thyroidectomy without radioiodine in low-risk thyroid cancer. N Engl J Med2022;386:923-932; doi: 10.1056/NEJMoa2111953.
7.
LeboulleuxS, BournaudC, ChougnetCN, et al.Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. Lancet Diabetes Endocrinol2025;13(1):38-46; doi: 10.1016/S2213-8587(24)00276-6.
